Pharma BD Deal Intelligence
Amgen / Generate Biomedicines, Inc.
2022 · Co-Development · $1.9B · Pending
This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2027 at the earliest for this deal, once/if it closes.
Key facts
- Announced Jan 06, 2022
- Deal value $1.9B
- Deal type Co-Development
Related deals
See the full interactive analysis, sources & comparables →
← Browse all deals ·
How we score deals
More: 2022 deals · Amgen deals